

Katalin Pungor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9421391/publications.pdf>

Version: 2024-02-01

8
papers

77
citations

1684188
5
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

64
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532092634.	2.7	24
2	Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2239-2248.	1.8	15
3	<p>Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1533-1542.	2.2	14
4	The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. <i>BMC Psychiatry</i> , 2021, 21, 300.	2.6	8
5	Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. <i>Comprehensive Psychiatry</i> , 2021, 107, 152233.	3.1	5
6	Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeksâ€™ Treatment in Patients with Clinically Stable Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 3197-3208.	2.2	5
7	<p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 681-690.	2.2	3
8	Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532098150.	2.7	3